Whitehawk Therapeutics, Inc. (WHWK)
NASDAQ: WHWK · Real-Time Price · USD
3.760
0.00 (0.00%)
At close: Oct 1, 2026, 4:00 PM EDT
3.740
-0.020 (-0.53%)
After-hours: Oct 1, 2026, 7:30 PM EDT
Whitehawk Therapeutics Employees
Whitehawk Therapeutics had 32 employees as of June 30, 2026. The number of employees increased by 11 or 52.38% compared to the same quarter last year.
Employees
32
Change
11
Growth
52.38%
Revenue / Employee
n/a
Profits / Employee
-$2,494,719
Market Cap
214.35M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 32 | 11 | 52.38% |
| Mar 31, 2026 | 29 | 11 | 61.11% |
| Dec 31, 2025 | 23 | -17 | -42.50% |
| Sep 30, 2025 | 22 | -31 | -58.49% |
| Jun 30, 2025 | 21 | -49 | -70.00% |
| Mar 31, 2025 | 18 | -57 | -76.00% |
| Dec 31, 2024 | 40 | -49 | -55.06% |
| Sep 30, 2024 | 53 | -35 | -39.77% |
| Jun 30, 2024 | 70 | -19 | -21.35% |
| Mar 31, 2024 | 75 | -5 | -6.25% |
| Dec 31, 2023 | 89 | 10 | 12.66% |
| Sep 30, 2023 | 88 | 12 | 15.79% |
| Jun 30, 2023 | 89 | 22 | 32.84% |
| Mar 31, 2023 | 80 | 26 | 48.15% |
| Dec 31, 2022 | 79 | 40 | 102.56% |
| Sep 30, 2022 | 76 | 55 | 261.90% |
| Jun 30, 2022 | 67 | 57 | 570.00% |
| Mar 31, 2022 | 54 | 44 | 440.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Adagene | 128 |
| Foghorn Therapeutics | 106 |
| Alector | 103 |
| Keros Therapeutics | 92 |
| Cartesian Therapeutics | 75 |
| Compugen | 75 |
| Anavex Life Sciences | 34 |
WHWK News
- 14 hours ago - Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer - TheFly
- 15 hours ago - Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 - PRNewsWire
- 1 day ago - Whitehawk Therapeutics initiated with a Buy at Stifel - TheFly
- 16 days ago - Whitehawk Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 17 days ago - Whitehawk Therapeutics presents PTK7 data at WCLC 2026 - TheFly
- 18 days ago - Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 - PRNewsWire
- 21 days ago - Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors - PRNewsWire
- 4 weeks ago - Whitehawk Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire